Dr. Sexton, a Board-Certified Orthopaedic surgeon, Fellow of the Arthroscopy Association of North America, and Army Veteran, joins one of the fastest-growing orthopaedic practices in Florida

TAMPA, Fla. - January 9, 2023 - (Newswire.com)

Orthopaedic Medical Group of Tampa Bay (OMG) is proud to announce the addition of Dr. Nick Sexton, orthopaedic surgeon, to their practice. 

Dr. Sexton, a Missouri native, comes to Orthopaedic Medical Group of Tampa Bay (OMGTB) with over 10 years of experience. He began his education directly out of high school when he attended the University of Missouri - Kansas City School of Medicine's six-year combined BA/MD program. During his time in medical school, he also worked to become a commissioned officer in the United States Army. Following medical school, Dr. Sexton completed his five-year surgical residency at Tripler Army Medical School in Hawaii and completed his subspecialty in orthopaedic sports medicine.

After residency, Dr. Sexton was stationed around the world working with U.S. and NATO forces as part of the 115th Combat Support Hospital in Afghanistan and Bassett Community Hospital in Alaska. During his time in the military, he gained valuable training and experience helping elite athletes, soldiers, sailors, airmen and marines. After separating from the military, Dr. Sexton moved to Oregon to begin private practice. 

Dr. Sexton spent over 10 years working in Oregon as a sports medicine specialist helping athletes from area high schools, colleges and universities get back to playing sports after sustaining injuries involving the hip, knee, and shoulder. While he treats a variety of injuries, including sprains, strains, fractures, and tears, he specializes in the treatment of complex rotator cuff injuries.

Orthopaedic Medical Group is one of the fastest-growing orthopaedic practices in Florida. The company credits this growth to its continued focus on quality outcomes, patient satisfaction, and delivering excellent orthopaedic care. OMG is proud to have Dr. Nick Sexton join their group and help to continue providing quality care and excellent patient outcomes in the greater Tampa Bay Area. You can call OMG at 813-684-2663 or visit www.OMGTB.com to schedule an appointment with Dr. Sexton.

Contact Information:
Spencer Beaudreault
Director of Marketing
[email protected]


Press Release Service by Newswire.com

Original Source: Orthopaedic Medical Group of Tampa Bay Introduces Nick Sexton, M.D.

New Logo Captures Company's Growth, Stability and Heritage

DULUTH, Ga. - January 9, 2023 - (Newswire.com)

Atlanta Dental announces the unveiling of a new logo and brand identity that supports the company's continued forward motion and digital transformation. Atlanta Dental is one of the nation's leading dental product and technology distributors supporting dentists as they deliver excellent clinical care, while also helping them build a fundamentally strong business. Founded in 1868, Atlanta Dental has grown into a diverse dental distributor with a rich heritage of service to the dental community. 

The new logo is designed to convey four core tenets of Atlanta Dental's long-term success: respect, trust, accountability and innovation. "Our new brand and logo express our commitment to meet our customers where they are, both on and offline and at their greatest point of need. This is consistent with the steps we have taken to innovate our digital strategy while continuing to deliver the highest quality products, technical service and the full support our customers expect," said Gary Kirkus, CEO of Atlanta Dental. 

While the new logo portrays graceful stability, it also serves as a strong anchor for Atlanta Dental's sub-brands.  

"The dental profession and the industry that supports it are continually in a state of transformation," said Tom Richardson, President of Atlanta Dental. "Our new logo represents our desire to contribute to our customers' success as their needs evolve, as well as our partners and our employees who meet and exceed customer expectations on a daily basis."

With its new corporate brand, Atlanta Dental is steadfast in its commitment to the advancement of dentistry and investment in its future. 

Atlanta Dental is independent, privately held, and employee-owned.

 Learn more by visiting AtlantaDental.com.

Contact Information:
Tom Richardson
President
[email protected]
678-584-4830


Press Release Service by Newswire.com

Original Source: Atlanta Dental Unveils New Logo and Brand Identity

The device's ease of use permits players to wear sam® for long periods discreetly, allowing athletes to attend class while maintaining 100% treatment compliance during recovery.

AUSTIN, Texas - January 9, 2023 - (Newswire.com)

A Texas collegiate football program is taking advantage of sustained acoustic medicine (sam®), a low-intensity, long-duration ultrasound treatment developed by ZetrOZ Systems. Injured athletes are utilizing the device while in class, allowing them to recover from injury and get the full benefit of the recommended one-hour treatment time without sacrificing attendance.

A representative from the ZetrOZ Systems sports medicine team visited the organization to discuss the sam® device. One account involved a wide receiver at the college who suffered from plantar fasciitis. His trainer put him on a treatment using the sam®x1 wireless unit, allowing him to attend team lunches and class while undergoing the full hour of treatment time.

An innovation in wearable health technology, sam® is a wearable, mechanobiological device that delivers high-frequency sound waves to the affected area, helping to increase blood flow while reducing inflammation and swelling. The increased oxygenated hemoglobin at the injury site removes cytokine enzymes and cellular waste and can be particularly useful for treating injuries such as strains, sprains, and muscle tears, as well as chronic conditions such as tendonitis and bursitis.

In addition to its anti-inflammatory effects, long-duration ultrasound therapy has also been found to reduce pain, improve mobility, and accelerate tissue repair. It is generally considered a safe and non-invasive treatment option with few side effects.

Backed by over 30 clinical studies, the sam® device was developed from research funded by the National Institute of Health and the U.S. Department of Defense to provide effective soft tissue healing and reduce the use of narcotics and invasive treatments. 

To learn more, visit zetroz.com.

About ZetrOZ Systems

ZetrOZ Systems is leading healing innovations in sports medicine and developing wearable bioelectronic devices for the delivery of sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on proprietary medical technology of +46 patents and is the exclusive manufacturer and developer of sam®, a product line designed for the treatment of acute and chronic musculoskeletal conditions. To learn more, visit zetroz.com.

Contact Information:
Buse Kayar
[email protected]


Press Release Service by Newswire.com

Original Source: Sustained Acoustic Medicine Enables Student-Athletes to Recover in the Classroom While Meeting Their Academic Obligations

SurgiVance, a leading innovator in developing AI-driven, direct-to-digital confocal pathology, announced today that Michael Li, PhD has been appointed Chief Executive Officer.

NEW YORK - January 9, 2023 - (Newswire.com)

"On behalf of the Board, we are very pleased to welcome Dr. Li to SurgiVance as the company is moving into a new phase of product development and commercialization, and to further its leadership position in advancing and innovating healthcare with the next generation direct-to-digital confocal pathology," said Dr.  Gareau, the founder and Chairman of Board at SurgiVance. "We are delighted that Dr. Li can join the SurgiVance team, and excited to have him as a partner on our journey. He is not only an experienced technology executive, but also a great strategic navigator, which is key in this exciting and rapidly evolving field."

Dr. Li brings with him many years of rich leadership experience in medical devices, healthcare, and technology, from R&D, to new product commercialization, to general management. He has held senior management positions in major multinationals such as Siemens Medical, as well as numerous medical device and IVD startups such as Neural Analytics. Dr. Li received his doctoral degree in physics from the University of Washington, Seattle.

"I am impressed by the technology advancement and significant innovations by Dr. Gareau and the SurgiVance team and I am excited to lead the team in moving the technology to market. Pathology is a corner stone of medical care. Hopefully, we will ease the existing true pain points experienced by physicians, improve patient care, and save more lives." said Dr. Li.

Contact Information:
Michael Li
Chief Executive Officer
[email protected]
802-448-2623

Daniel Gareau
President
[email protected]
802-448-2623
Related Files
SurgiVance_Tech.pdf



Press Release Service by Newswire.com

Original Source: SurgiVance, a Leading Healthcare Innovator, Announced Today That Michael Li, PhD Has Been Appointed Chief Executive Officer

New Value-Based Care Company Addresses Health Disparities Among Seniors in Rural America

MYRTLE BEACH, S.C. - January 9, 2023 - (Newswire.com)

Today, co-founders Brian Mathis and Kari Severson Snaza announced the launch of Oasis Health Partners, a new company focused on value-based care in rural America. The company is committed to building healthier communities by advancing primary care for seniors.

Every day, more than 10,000 people in the U.S. become eligible for Medicare*. Nearly 25 percent of these people live in rural communities where access to preventative care can be a challenge, resulting in a higher prevalence of chronic conditions, higher mortality rates and other health inequities.

Oasis is positioned to improve lives in these communities by supporting primary care providers with the data, analytics, technology, care teams and expertise they need to provide the best care possible, spend more time with their patients and thrive in value-based care. Primary care partners benefit from patient-specific data to help them identify at-risk and rising-risk patients, a tech-enabled platform to simplify their workflows and highly trained staff to augment their existing care teams. Patients enjoy dedicated health advocates and nurse practitioners, prevention and care management resources and better access to in-clinic, in-home and virtual care.

"Primary care is the foundation of our healthcare system. The evidence clearly shows access to high-quality, primary care leads to longer, healthier lives. When we empower primary care providers, we elevate the health of local communities across America," says Kari Severson Snaza, co-founder and president of Oasis Health Partners.

Mathis and Snaza, who are former colleagues, both have deep roots in value-based care with well-known names in the national healthcare space. Mathis, co-founder and chief executive officer of Oasis, served as chief strategy officer at Sevita, the largest provider of home and community-based health care in the U.S. and at Optum Care, the country's largest risk-bearing physician organization. Snaza most recently served as chief strategy officer for the Mayo Clinic following a 15-year career at UnitedHealth Group.

"We are thrilled to be partnering again and bringing together a uniquely experienced team that has dedicated their careers to working with physicians in value-based care," says Brian Mathis. "The platform we have developed enables primary care providers to access patient-specific reporting, improve their workflow, spend more time with the patients who need it most and receive incentives based on the overall health of their patients. This team and platform, combined with our strong partnerships with health plans will allow us to break down barriers to high-quality preventative care and build healthier communities."

The pair intend to use the best practices gained delivering value-based primary care across a wide variety of markets and populations to affect positive change in smaller communities starting in South Carolina and rapidly expanding into additional markets nationwide. Oasis is backed by well-known healthcare venture funds, including Triple Aim Partners and GV (formerly Google Ventures).

About Oasis Health Partners
Oasis Health Partners is a value-based healthcare company focused on building healthier communities by advancing primary care. Oasis partners with patients, providers and health plans to provide personalized, local care for seniors across America. For more information, please visit oasishealth.com.

-XXX-

Media: Interviews and photography are available upon request.

*Source: Medicare Payment Advisory Commission

Contact Information:
Regina Vaccari
Owner/Principal, Vaccari Communications
[email protected]
(702) 337-1781


Press Release Service by Newswire.com

Original Source: Seasoned Healthcare Executives Launch Oasis Health Partners

Gwen, her family and the creators of this monumental training manikin will be available for media interviews Jan. 23, 2023, 9:30am-11:30am at the Orange County Convention Center. Press passes must be secured by Jan. 17 for the Jan. 23, 2023, event.

ORLANDO, Fla. - January 9, 2023 - (Newswire.com)

Lifecast Body Simulation Global (Echo Healthcare), a leader in hyper-realistic training manikins, will debut the world's first Child with Down Syndrome training manikin Jan. 23 at the International Meeting on Simulation in Healthcare (IMSH) conference in Orlando, Florida. This realistic medical manikin was formed from a real-life 3D body scan of a seven-year-old girl with Down syndrome named Gwen and will be available to healthcare education facilities around the world to facilitate specialty and inclusive training in managing patients with Down syndrome.

Gwen was created by Lifecast Body Simulation and the University of Greenwich, which received support from the Down Syndrome Association. This debut is monumental in the world of medical education and is guaranteed to make waves at the largest international medical simulation conference held in the U.S. There is no other medical training manikin available that accurately represents a child with Down syndrome, making Gwen the first in the world. The Gwen manikin allows healthcare providers to become accurately trained on how to treat a patient with Down Syndrome. Given variations in their airway, stature and anatomy, without proper training, additional harm can be unintentionally done by medical providers.

Down syndrome is a genetic disorder caused when abnormal cell division results in extra genetic material from chromosome 21. While varied amongst patients, a few common physical traits of Down syndrome are low muscle tone, a difficult airway for intubation, smaller stature, toe gapping, almond-shaped eyes, a single deep crease across the center of the palm, smaller hands and feet - all of which are accurately represented in the Gwen manikin.

"We are thrilled to offer the world's first medical manikin focusing on Down syndrome. Children with Down Syndrome are truly amazing but also very complex to treat from a medical standpoint. Our goal with the Gwen manikin is to ensure every healthcare provider is properly trained for when they do encounter a child with Down Syndrome in their clinical practice so we can mitigate any risk and ultimately improve patient safety," says Kevin King, CEO of Lifecast Body Simulation Global.

The Gwen manikin, along with the real-life Gwen and her family, will be at the International Meeting on Simulation in Healthcare (IMSH) to meet with the local media on Jan. 23, 2023, from 9:30am - 11:30am in Echo Healthcare Booth #111. Press passes are required to enter the conference exhibit area to interview Gwen and her family, the creators of the Gwen manikin and healthcare providers. Please contact Nicole Sherk prior to Jan. 17 to secure your press pass.

Contact Information:
Nicole Sherk
Marketing Manager
[email protected]
9412330854


Press Release Service by Newswire.com

Original Source: The World's First Child With Down Syndrome Medical Training Manikin Debuts Jan. 23 at the International Meeting on Simulation in Healthcare in Orlando, Florida

•• Complete epithelial recovery was achieved by 67% of subjects receiving NEXAGON, as opposed to 27% receiving Vehicle alone •• NEXAGON was well-tolerated demonstrating a safety profile similar to vehicle •• Amber plans to initiate the NEXPEDE-1 Phase 2/3 clinical trial in subjects with PCED of various etiologies in Q1 2023 ••

SAN DIEGO - January 9, 2023 - (Newswire.com)

Amber Ophthalmics, Inc. (Amber), a privately held clinical-stage biopharmaceutical company focused on developing innovative therapies for rare ophthalmic diseases, today announced positive topline results from the Phase 2 randomized, double-masked, vehicle-controlled clinical trial (EXPEDE) evaluating two topically administered concentrations of NEXAGON^® (lufepirsen ophthalmic gel) for the treatment of persistent corneal epithelial defect (PCED), secondary to chemical and/or thermal injury (CTI).

Subjects meeting the eligibility criteria were randomized to receive NEXAGON high concentration, NEXAGON low concentration, or vehicle alone (control). Corneal epithelial recovery (primary endpoint) was defined as corneas exhibiting complete corneal re-epithelialization within the treatment period that is maintained for at least 28 continuous days (response + durability). An analysis of the data was performed once 35 patients of a planned 108 were enrolled and had completed the study. 

Subjects, with ages ranging from 7 to 75 years, had an average baseline corneal defect area of 46.67 mm² (4 to 176 mm²). Both NEXAGON concentrations were generally well tolerated and demonstrated a similar safety profile to those receiving Vehicle alone. When the primary endpoint was assessed, both NEXAGON high (n=12) and low dose (n=12) treatment groups achieved 66.7% corneal epithelial recovery, as compared to 27.3% of those receiving Vehicle (n=11), a clinically meaningful difference of 39.4% (Fisher's exact test: p=0.065). Amber plans to submit these findings for inclusion at the upcoming 2023 ARVO meeting to be held in New Orleans, LA.

"These findings demonstrate the potential for NEXAGON to transform the current PCED treatment paradigm, and with recently received FDA guidance in hand, we are excited to initiate the NEXPEDE-1 study imminently," said Dr. Shawn A. Scranton, President and CSO of Amber. "We anticipate the study will begin enrolling subjects with PCED of various etiologies as soon as Q1 2023."

NEXAGON (lufepirsen ophthalmic gel) is a first-in-class, patent protected, naturally occurring, unmodified antisense oligonucleotide that restores ocular surface homeostasis by downregulating pathogenically elevated connexin 43 protein transcription. This prohibits connexin 43 hemichannel formation, quelling unregulated inflammation associated with PCED. NEXAGON has been granted orphan drug designation by the FDA for the indication of PCED.

PCED is a rare and progressive disease impacting an estimated 100,000 patients in the United States per year that arises from the failure of corneal re-epithelialization within 10-14 days of a corneal insult, even with the use of standard supportive treatment. Despite treatment, and regardless of underlying etiology, if progression is not halted PCED can result in corneal scarring, vascularization, and/or severe vision loss. There are currently no FDA approved therapies for the treatment of PCED. 

To find out more about Amber, NEXAGON or PCED, please visit our website www.amberophthalmics.com.

Contact Information:
Jill Jene, PhD
CBO, Amber Ophthalmics
[email protected]


Press Release Service by Newswire.com

Original Source: Amber Ophthalmics Announces Positive Topline Phase 2 Data Evaluating NEXAGON® for the Treatment of Persistent Corneal Epithelial Defect (PCED)